Imidapril

Summary

Imidapril (CHEMBL317094) is an approved small-molecule antihypertensive agent (ATC C09AA16) targeting ACE; indicated across 3 conditions including cardiovascular disorder and essential hypertension.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C09AA16
• Targets: 1 (ACE)
• Indications: 3 conditions
• Clinical trials: 3
• Chemistry: 405.4 Da · C20H27N3O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL317094
Name	Imidapril
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5464343
ChEBI	CHEBI:135654
ATC	C09AA16
Molecular formula	C20H27N3O6
Molecular weight	405.4
InChIKey	KLZWOWYOHUKJIG-BPUTZDHNSA-N

SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O

IUPAC name: (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid

ChEBI definition: A member of the class of imidazolidines that is (4S)-1-methyl-2-oxoimidazolidine-4-carboxylic acid in which the hydrogen of the imidazolidine nitrogen has been substituted by (1S)-1-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}ethyl group. It is the prodrug for imidaprilat, an ACE inhibitor used for the treatment of chronic heart failure.

Pharmacological roles (ChEBI): antihypertensive agent, EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, prodrug.

Also known as: Hipertene, Imidapril, Imidapril hcl, Imidapril hydrochloride, Imidapril monohydrochloride, TA 6366, TA-6366, Tanatril, IMIDAPRIL, Imidapril hydrochlorideÊ, Imidapril hydrochlorideÂ, Imidapril HCl

Parent form; salt/anhydrous children: CHEMBL3183293

Patent coverage: 2,294 distinct patent families (9,592 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ACE	Angiotensin-converting enzyme	Inhibition		0.7%	P12821

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Angiotensin-converting enzyme, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ACE	5	IC50	9900	nM	CHEMBL_ACT_851172

Target pathways

Aggregated over 1 target gene(s): ACE.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Metabolism of Angiotensinogen to Angiotensins	1	ACE
Peptide hormone metabolism	1	ACE
Metabolism of proteins	1	ACE

Dominant GO biological processes

GO term	Targets
kidney development	1
blood vessel remodeling	1
angiotensin maturation	1
regulation of renal output by angiotensin	1
neutrophil mediated immunity	1
antigen processing and presentation of peptide antigen via MHC class I	1
regulation of systemic arterial blood pressure by renin-angiotensin	1
positive regulation of systemic arterial blood pressure	1
proteolysis	1
spermatogenesis	1
regulation of blood pressure	1
male gonad development	1
post-transcriptional regulation of gene expression	1
negative regulation of gene expression	1
substance P catabolic process	1

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
essential hypertension	3	MONDO:0001134	MONDO:0001134
autosomal dominant polycystic kidney disease	2	MONDO:0004691	EFO:1001496

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00644475	PHASE3	UNKNOWN	Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension
NCT01230034	PHASE3	UNKNOWN	Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria
NCT00890279	PHASE2	UNKNOWN	Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 3 clinical and 5 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

32 molecules share ≥1 primary target. Top 32 by shared-target count:

Molecule	Source	Status	Shared targets
CAPTOPRIL	ChEMBL + PubChem	Phase 4 (approved)	ACE
LOSARTAN	ChEMBL + PubChem	Phase 4 (approved)	ACE
PERINDOPRIL	ChEMBL + PubChem	Phase 4 (approved)	ACE
SITAGLIPTIN	ChEMBL + PubChem	Phase 4 (approved)	ACE
BENAZEPRIL	ChEMBL	Phase 4 (approved)	ACE
ENALAPRIL	ChEMBL	Phase 4 (approved)	ACE
ENALAPRILAT	ChEMBL	Phase 4 (approved)	ACE
FOSINOPRIL	ChEMBL	Phase 4 (approved)	ACE
LISINOPRIL	ChEMBL	Phase 4 (approved)	ACE
MOEXIPRIL	ChEMBL	Phase 4 (approved)	ACE
QUINAPRIL	ChEMBL	Phase 4 (approved)	ACE
RAMIPRIL	ChEMBL	Phase 4 (approved)	ACE
TELMISARTAN	ChEMBL	Phase 4 (approved)	ACE
TRANDOLAPRIL	ChEMBL	Phase 4 (approved)	ACE
EDETIC ACID	ChEMBL	Phase 3	ACE
QUINAPRILAT	ChEMBL + PubChem	Phase 2 (approved)	ACE
BENAZEPRILAT	ChEMBL	Phase 2	ACE
CERONAPRIL	ChEMBL	Phase 2	ACE
FOSINOPRILAT	ChEMBL	Phase 2	ACE
IMIDAPRILAT	ChEMBL	Phase 2	ACE
LIBENZAPRIL	ChEMBL	Phase 2	ACE
MOEXIPRILAT	ChEMBL	Phase 2	ACE
OMAPATRILAT	ChEMBL	Phase 2	ACE
PROLINE	ChEMBL	Phase 2	ACE
RENTIAPRIL	ChEMBL	Phase 2	ACE
SAMPATRILAT	ChEMBL	Phase 2	ACE
SPIRAPRILAT	ChEMBL	Phase 2	ACE
TEPROTIDE	ChEMBL	Phase 2	ACE
ZOFENOPRIL	ChEMBL	Phase 2	ACE
Gallic Acid	PubChem	Approved	ACE
Hydrochlorothiazide	PubChem	Approved	ACE
Paclitaxel	PubChem	Approved	ACE